Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (TPS >= 50%) (HARMONi-7).

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Not Available

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

11-04-2025

Trial Type:

Treatment

Protocol ID:

VICCTHO25003

National Clinical Trial ID:

NCT06767514

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available